(Q41689551)

7 October 2017

1 reference

title

Cardiovascular toxicity with cancer chemotherapy (English)

1 reference

7 October 2017

1 reference

1

Frishman WH

1 reference

7 October 2017

Sung HM

2

1 reference

7 October 2017

Yee HC

3

1 reference

7 October 2017

Liu LL

4

1 reference

7 October 2017

Keefe D

5

1 reference

7 October 2017

Einzig AI

6

1 reference

7 October 2017

Dutcher J

7

1 reference

7 October 2017

language of work or name

1 reference

1 November 1997

1 reference

Current Problems in Cancer

7 October 2017

published in

1 reference

7 October 2017

volume

21

1 reference

7 October 2017

issue

6

1 reference

7 October 2017

page(s)

301-360

1 reference

Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia

7 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Altretamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cancer chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Ischemic cardiopathy from cis-diamminedichloroplatinum (CDDP)

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Cardiac toxicity of 5-fluorouracil: a study on 1083 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Symptomatic cardiotoxicity with high-dose 5-fluorouracil infusion: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Clinical cardiotoxicity of 5-fluorouracil

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Continuous ambulatory ECG monitoring during fluorouracil therapy: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Cardiac toxicity from antitumor therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

The syndrome of 5-fluorouracil cardiotoxicity. An elusive cardiopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Fluorouracil cardiotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

The clinical syndrome of 5-fluorouracil cardiotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

5-Fluorouracil-associated cardiotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Prinzmetal's angina during 5-fluorouracil chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

5-Fluorouracil cardiotoxicity: left ventricular dysfunction and effect of coronary vasodilators

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

5-Fluorouracil-induced coronary vasospasm

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Ischemic chest pain after 5-fluorouracil therapy for cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Thrombogenicity of intravenous 5-fluorouracil alone or in combination with cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Toxic cardiogenic shock associated with infusion of 5-fluorouracil

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Profound, yet reversible, heart failure secondary to 5-fluorouracil

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Cardiotoxic effects of 5-fluorouracil in the guinea pig

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Cardiotoxicity of 5-fluorouracil

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Cardiotoxicity of commercial 5-fluorouracil vials stems from the alkaline hydrolysis of this drug

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Fluoroacetaldehyde as cardiotoxic impurity in fluorouracil (Roche)

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Prediction of cardiovascular complications in patients with prostatic cancer treated with estrogen

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Tamoxifen as adjuvant therapy in breast cancer. Current status

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five-drug chemotherapy regimen. A study of 159 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Tamoxifen treatment of metastatic breast cancer and antithrombin III levels

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Oral contraceptives and low antithrombin-3 concentration

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Effects of tamoxifen on blood coagulation

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Serum lipoproteins and proteins after breast cancer surgery and effects of tamoxifen

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Clinical Pharmacology of Estrogens: Cardiovascular Actions and Cardioprotective Benefits of Replacement Therapy in Postmenopausal Women

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Variable expression of the estrogen receptor in normal and atherosclerotic coronary arteries of premenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Pulsatility index in internal carotid artery in relation to transdermal oestradiol and time since menopause

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Comparison of Zoladex, diethylstilbestrol and cyproterone acetate treatment in advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Comparison of Diethylstilbestrol, Cyproterone Acetate and Medroxyprogesterone Acetate in the Treatment of Advanced Prostatic Cancer: Final Analysis of a Randomized Phase III Trial of the European Organization for Research on Treatment of Cancer Urolo

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Bleomycin and Raynaud's phenomenon

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Anthracycline-induced cardiotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Doxorubicin-induced cardiac toxicity.

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Early anthracycline cardiotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Doxorubicin Cardiomyopathy: Evaluation by Phonocardiography, Endomyocardial Biopsy, and Cardiac Catheterization

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Risk factors for doxorubicin-induced congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

The anthracycline antineoplastic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Adriamycin. A new anticancer drug with significant clinical activity

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Outcome of clinical congestive heart failure induced by anthracycline chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Strategies for prevention of anthracycline cardiotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Role of the glutathione-glutathione peroxidase cycle in the cytotoxicity of the anticancer quinones

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Enhancement of reactive oxygen-dependent mitochondrial membrane lipid peroxidation by the anticancer drug adriamycin

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Role of daunosamine and hydroxyacetyl side chain in reaction with iron and lipid peroxidation by anthracyclines.

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Hydroxyl radical production and DNA damage induced by anthracycline-iron complex

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Oxidative destruction of erythrocyte ghost membranes catalyzed by the doxorubicin-iron complex

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Generation of hydroxyl radicals during the enzymatic reductions of the Fe3+-ADP-phosphate-adriamycin and Fe3+-ADP-EDTA systems. Less involvement of hydroxyl radical and a great importance of proposed perferryl ion complexes in lipid peroxidation

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Differences in O2 reduction by the iron complexes of adriamycin and daunomycin: the importance of the sidechain hydroxyl group

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Prevention of doxorubicin cardiac toxicity in the mouse by N-acetylcysteine

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Anthracyclines and the heart

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

A new insight into adriamycin-induced cardiotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Exercise echocardiography in the detection of anthracycline cardiotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Dobutamine stress echocardiography: a sensitive indicator of diminished myocardial function in asymptomatic doxorubicin-treated long-term survivors of childhood cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Prolongation of isovolumetric relaxation time as assessed by Doppler echocardiography predicts doxorubicin-induced systolic dysfunction in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Early detection of doxorubicin cardiotoxicity: interest of Doppler echocardiographic analysis of left ventricular filling dynamics

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Detection of adriamycin cardiotoxicity with indium-111 labeled antimyosin monoclonal antibody imaging

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Clinical role of indium-111 antimyosin imaging

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Assessment of anthracycline-induced myocardial damage by quantitative indium 111 myosin-specific monoclonal antibody studies

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Doxorubicin cardiotoxicity detected by indium 111 myosin-specific imaging

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Myocardial uptake of 111In monoclonal antimyosin Fab in detecting doxorubicin cardiotoxicity in rats. Morphological and hemodynamic findings

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

I-123 MIBG and Serial Radionuclide Angiocardiography in Doxorubicin-related Cardiotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Noninvasive identification of anthracycline cardiotoxicity: comparison of 123I-MIBG and 123I-BMIPP imaging

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Detection of adriamycin-induced cardiotoxicity in cultured heart cells with technetium 99m-SESTAMIBI

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Atrial natriuretic peptide as a marker for doxorubicin-induced cardiotoxic effects

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Reduced cardiotoxicity of doxorubicin by a 6-hour infusion regimen. A prospective randomized evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Prospective evaluation of cardiotoxicity during a six-hour doxorubicin infusion regimen in women with adenocarcinoma of the breast

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

ICRF-187 permits longer treatment with doxorubicin in women with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Amelioration of chronic anthracycline cardiotoxicity by ICRF-187 and other compounds

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Characterization of histamine secretion induced by anthracyclines in rat peritoneal mast cells

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Amelioration of 4'-epidoxorubicin-induced cardiotoxicity by sodium cromoglycate

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Cardiotoxic effects and the influence on the beta-adrenoceptor function of doxorubicin (Adriamycin) in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Probucol protects against adriamycin cardiomyopathy without interfering with its antitumor effect

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Experimental systemic toxicology of 4'-epidoxorubicin, a new, less cardiotoxic anthracycline antitumor agent

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Evaluation of anthracycline cardiotoxicity with the model of isolated, perfused rat heart: comparison of new analogues versus doxorubicin

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Cardiotoxicity of epirubicin and doxorubicin: a double-blind randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Pharmacological Properties of Oral Idarubicin

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

A prospective randomized trial of doxorubicinversus idarubicin in the treatment of advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

New anthracycline analogs in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

A randomized comparison of single-agent doxorubicin and epirubicin as first-line cytotoxic therapy in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Cardiovascular consequences of recombinant DNA technology: interleukin-2.

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Myocardial injury after interleukin-2 therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Interleukin-2 administration causes reversible hemodynamic changes and left ventricular dysfunction similar to those seen in septic shock.

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

The hemodynamic effects of treatment with interleukin-2 and lymphokine-activated killer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Septic shock. Hemodynamics and pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Evaluation of the cardiovascular toxicity related to cancer immunotherapy with interleukin-2 by monitoring atrial natriuretic peptide secretion: a case report

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Recombinant interleukin-2 and recombinant interferon alpha immunotherapy cardiovascular toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Myocardial toxic effects during recombinant interleukin-2 therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Cardiorespiratory effects of immunotherapy with interleukin-2.

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Myocarditis or acute myocardial infarction associated with interleukin-2 therapy for cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Pathologic findings associated with interleukin-2-based immunotherapy for cancer: a postmortem study of 19 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Eosinophilic myocarditis associated with high-dose interleukin-2 therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Prevention of viral myocarditis with recombinant human leukocyte interferon alpha A/D in a murine model

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Pathogenesis and preventive and therapeutic trials in an animal model of dilated cardiomyopathy induced by a virus

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Protective effect of recombinant alpha interferon on coxsackievirus B3 myocarditis in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Toxic Effects of Interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Comparison of intramuscular and intravenous recombinant alpha-2 interferon in melanoma and other cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Reversible arrhythmias observed in patients treated with recombinant alpha 2 interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Recombinant alpha 2 interferon-related cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Clinical toxicity of interferons in cancer patients: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Cardiotoxicity of interferon. A review of 44 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Sequences of taxol and cisplatin: a phase I and pharmacologic study

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Evaluation of taxol cardiotoxicity in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

An overview of experience with TAXOL (paclitaxel) in the U.S.A.

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere).

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Paclitaxel (TAXOL): side effects and patient education issues

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Taxol in advanced, hormone-refractory carcinoma of the prostate. A phase II trial of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group Results

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Cardiac disturbances during the administration of taxol

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Phase I trial of Taxotere: five-day schedule

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour intravenous infusion

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980001-3

7 January 2021

10.1016/S0147-0272(97)80001-3

Identifiers

DOI

1 reference

release_5h7jiu4buvek7f7m3cedthgyuu

7 October 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/5h7jiu4buvek7f7m3cedthgyuu

24 November 2022

mapped directly with Wikidata item

1 reference